Liu et al. [72] discovered that ATL III activates anti-tumor immunity by inhibiting the phosphorylation of Jak3, Stat3, and the nuclear translocation of Stat3, and downregulating the expression of IDO in interferon-γ-induced lung cancer cells, and its interaction site with Jak3 protein is leucine 905. Here, JAK3 is linked to lung cancer.